Clinical Trials Browser

Phase 2 × Lymphoma, Follicular × pirtobrutinib × Clear all

NCT06948786 2025-11-26

Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial

Phase 2 Recruiting

Lymphoma, Follicular